Brief: Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
05/12/2025 14:01
Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABILITY COHORT 1 DATA OF AMX0114 IN ALS FROM FIRST-IN-HUMAN LUMINA TRIAL AMYLYX PHARMACEUTICALS INC - AMX0114 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text: ID:nBw68TDlNa Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock